Literature DB >> 21058437

The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer.

Akiko Abe1, Hiroyuki Furumoto, Minoru Irahara, Hiroyasu Ino, Masaharu Kamada, Osamu Naka, Masaru Sasaki, Toshiaki Kagawa, Osamu Okitsu, Norio Kushiki.   

Abstract

AIM: The objective of this study was to verify the impact of systematic retroperitoneal lymphadenectomy on survival in patients with ovarian cancer. MATERIAL &
METHODS: During 2001–2005, clinical records of 118 patients with epithelial ovarian cancer were collected in Tokushima prefecture. From a number of hospitals, patients in one group were treated without systematic lymphadenectomy, and in another group, patients were treated with routine systematic lymphadenectomy. Clinical records were reviewed retrospectively and progression-free survival (PFS) and overall survival (OS) were compared.
RESULTS: Sixty-two patients were staged as I–II according to the macroscopic findings at surgery. Forty of these patients received systematic lymphadenectomy and 22 patients did not. The 5-year OS was 100 and 80%, respectively (P = 0.07). The 5-year PFS was 94 and 71%, respectively (P = 0.04). In patients with clear cell adenocarcinoma, 3-year OS and PFS were significantly better in the lymphadenectomy group (P = 0.01, P = 0.046, respectively). The 56 patients staged as III–IV according to the macroscopic findings at surgery were optimally debulked. Twenty-eight of these patients received systematic lymphadenectomy and 28 patients did not. There is no difference in the 5-year OS (65 and 66%, respectively; P = 0.71) or the 5-year PFS (30 and 52%, respectively; P = 0.48).
CONCLUSION: This study has demonstrated that the systematic lymphadenectomy had benefit only in patients with ovarian cancer macroscopically confined to the pelvis. In patients with clear cell adenocarcinoma, systematic lymphadenectomy was beneficial. To the contrary, systematic lymphadenectomy had no benefit on OS or PFS in patients with advanced ovarian cancer if optimally debulked.

Entities:  

Mesh:

Year:  2010        PMID: 21058437     DOI: 10.1111/j.1447-0756.2010.01274.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  9 in total

1.  Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Authors:  Cornelia Bachmann; Robert Bachmann; Bernhard Kraemer; Sara Yvonne Brucker; Anette Staebler; Falko Fend; Ralf Rothmund; Diethelm Wallwiener
Journal:  Mol Clin Oncol       Date:  2016-08-05

2.  Nodal status--its impact on prognosis in advanced ovarian cancer.

Authors:  C Bachmann; S Bachmann; T Fehm; A Staebler; S Becker; R Rothmund; C Gardanis; E M Grischke; D Wallwiener; E F Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

3.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

4.  Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.

Authors:  Jennifer J Mueller; Marie Holzapfel; Chan H Han; Kevin Santos; Camille Gunderson; Kathleen Moore; Britt Erickson; Charles A Leath; Elena Diaz; Christine Walsh; Stephanie L Wethington; Sheila Z Dejbakhsh; Richard R Barakat; Ginger J Gardner; David M Hyman; Robert A Soslow; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

5.  Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment.

Authors:  Cornelia Bachmann; Robert Bachmann; Falko Fend; Diethelm Wallwiener
Journal:  J Cancer       Date:  2016-11-09       Impact factor: 4.207

6.  The value of systematic lymphadenectomy during debulking surgery in the treatment of ovarian cancer: a meta-analysis of randomized controlled trials.

Authors:  Qingqing Lin; Wenchao Liu; Song Xu; Juan Li; Jinyi Tong
Journal:  J Ovarian Res       Date:  2020-05-08       Impact factor: 4.234

7.  The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer.

Authors:  Ting Deng; Qidan Huang; Ting Wan; Xiaoling Luo; Yanling Feng; He Huang; Jihong Liu
Journal:  J Gynecol Oncol       Date:  2021-05       Impact factor: 4.401

8.  Assessment of Lymph Node Involvement with PET-CT in Advanced Epithelial Ovarian Cancer. A FRANCOGYN Group Study.

Authors:  Antoine Tardieu; Lobna Ouldamer; François Margueritte; Lauranne Rossard; Aymeline Lacorre; Nicolas Bourdel; Guillaume Lades; Camille Sallée; Jacques Monteil; Tristan Gauthier
Journal:  J Clin Med       Date:  2021-02-05       Impact factor: 4.241

9.  Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis.

Authors:  Tatsuyuki Chiyoda; Manabu Sakurai; Toyomi Satoh; Satoru Nagase; Mikio Mikami; Hidetaka Katabuchi; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2020-09       Impact factor: 4.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.